The Covid vaccine developed by the University of Oxford, in collaboration with the pharmaceutical company AstraZeneca generates a strong immune response among the elderly, the most vulnerable group: what Financial Times, speaking of the hopes generated by the trials. The clinical trials of this vaccine are in Phase 3, the (final) that verifies the candidate’s effectiveness and safety in thousands of people.
The good news
Two sources cited by the newspaper as aware of ongoing studies, argued that the vaccine in question generates antibodies and so-called T lymphocytes (the first line of defense of the immune system) among the elderly. It would be important because generally the immune system of the elderly less reactive, so much so that improved vaccines are usually studied specifically for them. The new results are in line with data published in July, which showed robust immune responses in a group of healthy adults aged 18 to 55, generated by the vaccine developed by the University of Oxford. The AstraZeneca vaccine is one of three options offered by Europe (and therefore Italy). The Jenner Institute University of Oxford is developing the vaccine in partnership with the Irbm (Molecular Biology Research Institute) of Pomezia: In the Phase 1 trials already published, the vaccine showed 90% efficacy which with reinforcement can reach 95%, declared Piero Di Lorenzo, president of Irbm.
Data are preliminary, unprecedented and in any case it is necessary to wait for the completion of Phase 3. However, the European Medicines Agency (Ema) has started to analyze the data provided by the manufacturer to give rapid approval before placing the vaccine on the market. The Oxford vaccine route paused in September after a adverse reaction of a participant. The studies were then resumed first in Britain and then around the world (United States, Brazil, South Africa). Regulatory agencies usually take months to examine the documents in detail: there are two types of approval / registration for a vaccine, the classic one, then there is the emergency one. If the pandemic continues to increase in late November, approval can also come in a few weeks, that a very short time. If there is an approval for emergency use, then, quickly, the vaccine can be registered until January, he told everyone Health Courier Sergio Abrignani, immunologist, professor of General Pathology at the State University of Milan and director of the National Institute of Molecular Genetics “Romeo and Enrica Invernizzi”, explaining the process that vaccines now follow (in this case, that of Pfizer). Having the vaccine by the end of the year, remember, does not mean that the entire population will be vaccinated immediately. Italy will have a few million doses available to people at risk and health professionals, but to finish the first vaccinations it may take until springtherefore, a winter yet to be faced with responsibility and care.
October 26, 2020 (change on October 26, 2020 | 13:50)
© RESERVED REPRODUCTION